Douglass Brian Robb
Known title: CHIEF PRODUCT OFFICERCIK: 0002104618
Associated companies
Transaction History
| RGEN | ▼ Sell | Tax Withholding | 334 | $42K | 5/7/2026 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 221 | $28K | 3/2/2026 | View on chart |
| RGEN | ▲ Buy | Grant | 2,288 | $0 | 12/31/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Repligen Completes BioLife Solutions Acquisition
Repligen has finalized its acquisition of BioLife Solutions, a move that follows shareholder approval of the merger. This transaction expands Repligen's portfolio in the biopharmaceutical sector. The stock recently reached a 52-week high, reflecting market interest in the company's growth strategy.
Repligen Completes BioLife Solutions Acquisition. Repligen has finalized its acquisition of BioLife Solutions, a move that follows shareholder approval of the merger. This transaction expands Repligen's portfolio in the biopharmaceutical sector. The stock recently reached a 52-week high, reflecting market interest in the company's growth strategy.